Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds
With Neuron23, Westlake Unveils Second Start-Up In A Week
Executive Summary
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
You may also be interested in...
Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III
Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.